- Home
- / Matinas BioPharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Matinas BioPharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.8
2024-10-29
Market Capitalization
$14 M
2024-10-29
Revenue
$1.1 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 194.5K | 149.7K | 119.8K | 89.8K | 158.3K | 33.3K | 3.2M | 1.1M | ||||
| General and administrative expense | 5.3M | 4.8M | 4.3M | 7.6M | 8.0M | 7.8M | 10.0M | 10.2M | 11.1M | 10.4M | 8.7M | 6.9M |
| Operating expense total | 10.5M | 10.1M | 8.3M | 16.7M | 14.8M | 19.0M | 24.4M | 27.8M | 24.9M | 20.2M | 7.0M | |
| Depreciation and amortization | 32.0K | |||||||||||
| EBIT | (10.5M) | (9.9M) | (8.3M) | (16.5M) | (14.6M) | (18.9M) | (24.2M) | (24.7M) | (24.6M) | (23.8M) | (24.6M) | (7.0M) |
| EBIT margin, % | -5096.0% | -11024.6% | -12230.9% | -21067.4% | -15288.4% | -771.3% | -2168.4% | |||||
| Interest income | 686.4K | 122.9K | ||||||||||
| Interest expense | 25.2K | 19.6K | 16.5K | 22.0K | 56.6K | |||||||
| Pre tax profit | (24.3M) | (10.3M) | ||||||||||
| Income tax expense | 270.0K | (357.0K) | (506.9K) | (80.0K) | 7.0K | |||||||
| Net Income | (10.2M) | (9.1M) | (7.6M) | (15.5M) | (14.1M) | (17.4M) | (22.4M) | (23.3M) | (21.0M) | (22.9M) | (24.3M) | (10.3M) |
| EPS | (0.1) | (5.0) | (2.0) |